In summary, we present a novel combinatorial prognostic model for MSS and MSI CRC patients, based on 3 independent features: IZ Immunogradient indicators of CD8+ and CD20+ cell densities and infiltrative tumor growth pattern assessed by pathologist. The gene discussed is CD8A; the disease is colorectal carcinoma.